New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
16:24 EDTFATEFate Therapeutics announces FDA clearance of IND for PROHEMA
Fate Therapeutics announced that the FDA has cleared its Investigational New Drug Application, or IND, for the clinical development of PROHEMA in pediatric patients undergoing hematopoietic stem cell transplantation for the treatment of inherited metabolic disorders, or IMDs. The FDA's clearance of the IND allows the company to begin expanding its clinical investigation of PROHEMA into rare, non-malignant disorders. The company plans to initiate enrollment of the PROVIDE trial in pediatric patients with IMDs in Q4.
News For FATE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:16 EDTFATEPiper Jaffray and the Alliance for Regenerative Medicine co-host conference
3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use